Affimed N.V. (AFMD) News
Filter AFMD News Items
AFMD News Results
|Loading, please wait...|
AFMD News Highlights
- For AFMD, its 30 day story count is now at 6.
- Over the past 16 days, the trend for AFMD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AB, DRUG and HOUR are the most mentioned tickers in articles about AFMD.
Latest AFMD News From Around the Web
Below are the latest news stories about AFFIMED NV that investors may wish to consider to help them evaluate AFMD as an investment opportunity.
Compugen Ltd. (NASDAQ:CGEN) with the stream of 2.15% also noticed, India Affimed N.V. (NASDAQ:AFMD) encountered a rapid change of 0.86% in the last hour of Tuesday’s trading session. Compugen Ltd. … The post Volatile Stock to Watch: Compugen Ltd. (NASDAQ:CGEN 2.15%), Affimed N.V. (NASDAQ:AFMD 0.86%) appeared first on Stocks Equity .
In Monday’s session, Affimed N.V. (NASDAQ:AFMD) marked $1.16 per share, down from $1.22 in the previous session. While Affimed N.V. has underperformed by -4.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -71.98%, with highs and lows ranging from $5.10 to $1.03, whereas […]
Affimed N.V. (NASDAQ:AFMD) marked $1.15 per share on Tuesday, up from a previous closing price of $1.14. While Affimed N.V. has overperformed by 0.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -73.92%, with highs and lows ranging from $5.10 to $1.03, whereas […]
The trading price of Affimed N.V. (NASDAQ:AFMD) closed higher on Friday, January 13, closing at $1.14, 0.88% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $1.085 and $1.15. In examining the 52-week price action we see that the stock hit a 52-week high … These Numbers Reveal How Powerful Affimed N.V. (NASDAQ: AFMD) Stock Is Read More »
Affimed N.V. (NASDAQ:AFMD)’s traded shares stood at 2.18 million during the last session, with the company’s beta value hitting 2.37. At the close of trading, the stock’s price was $1.13, to imply an increase of 5.61% or $0.06 in intraday trading. The AFMD share’s 52-week high remains $5.10, putting it -351.33% down since that peak … Affimed N.V. (NASDAQ: AFMD) Fell -351.33% From Highs, What Does The Future Hold? Read More »
AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for IND filing in H1 2023 and initiation of clinical study during 2023AFM24: Data updates from the three AFM24 ongoing studies are expected at scientific conferences in Q2/Q3 2023AFM28: Clinical trial application (CTA) cleared in France and Spain with additional filings in European countries pending; initiation of phase 1 study is expected in Q2 202
Affimed N.V. (AFMD)’s stock has witnessed a price hike of 3.63% from the previous close with its current price standing at $1.28. Its current price is -77.73% under its 52-week high of $5.77 and 24.76% more than its 52-week low of $1.03. Based on the past 30-day period, the stock price is -40.23% below the […]
Affimed N.V. (NASDAQ:AFMD) shares, rose in value on Thursday, December 29, with the stock price up by 3.51% to the previous day’s close as strong demand from buyers drove the stock to $1.18. Actively observing the price movement in the recent trading, the stock is buoying the session at $1.14, falling within a range of … Understanding Affimed N.V. (NASDAQ: AFMD)’s Growth Potential Read More »
Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of AFM28 clinical development in the first half of 2023 on track HEIDELBERG, Germany, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced to